Peer-reviewed veterinary case report
DR-70 blood test predicts survival in dogs with tumors
By Ke, Chiao-Hsu et al.·Published in The veterinary quarterly·2024·Department of Veterinary Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: DR-70 (fibrinogen-fibrin degradation products) as a prognostic biomarker in dogs with neoplasms.
- Species:
- dog
Plain-English summary
A group of 195 dogs with tumors was studied to see if a blood test measuring fibrinogen-fibrin degradation products (DR-70) could help predict how long they might live. The results showed that dogs with higher levels of DR-70 (above 1.514 µg/mL) tended to have shorter survival times. Additionally, dogs that responded well to treatment had lower DR-70 levels over time, while those whose condition worsened had increasing levels. This suggests that monitoring DR-70 could help veterinarians assess how a dog with cancer is responding to treatment and predict their prognosis.
People also search for: dog cancer prognosis · DR-70 blood test for dogs · how to treat dog tumors · dog survival rates with cancer
Abstract
Fibrinogen-fibrin degradation products (DR-70) are derived from tumor cells or metastases. Our previous study reported the diagnostic values in dogs with tumors, but no research has yet to be conducted to establish DR-70 as a prognostic marker. Herein, we investigated changes in DR-70 concentrations and disease courses in dogs with tumors. Overall survival time (OST) analysis was performed in 195 dogs with tumors, stratified with a recommended cut-off (1.514 µg/mL). Continual DR-70 measurements were performed during the medical interventions of 27 dogs with neoplasms. Clinical conditions and medical records were retrospectively reviewed. According to a cut-off value, dogs with plasma DR-70 concentrations above 1.514 µg/mL had shorter survival rates than those with concentrations below this threshold. In cases with complete or partial remission in response to treatment, the DR-70 concentration was decreased compared with that at the first visit, whereas it was increased in patients with disease progression. Our study suggested that changes in DR-70 concentration can be used as a prognostic biomarker for canine neoplasms. Furthermore, increased plasma DR-70 levels might be associated with shorter survival, and DR-70 concentrations may reflect responses to medical intervention.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39028259/